News About: Pharm. Affairs
Preemptive attack of Sanofi to launch Toujeo next month in novel basal insulin competition
Sanofi-Aventis has created a foundation to be a step ahead in the competition of a novel insulin against Novo Nordisk.
According to Sanofi, ‘Toujeo(generic name: insulin glargine),’ a next-generation once-daily long-...
Expectation in ‘complexes’ after erectile dysfunction treatments
Due to the generics launched after patent expirations of the original erectile dysfunction products, ‘Viagra(sildenafil)’ and ‘Cialis(tadalafil),’ generics have raged in the urology market.
Generic products, which ha...
Seoul with most doctors and Gwangju with most pharmacists
It was observed the patient-per-medical-personnel ratio was 180 physicians and 284 pharmacists per 100 thousand people in 2014.
According to the ‘2014 Annual Statistical Report of Regional Medical Use’ which was rece...
The entry of Supect’s primary treatment is drawing near
‘Supect(ladotinib),’ a domestic new drug for chronic myeloid leukemia(CML), will soon become a primary treatment.
According to the industry concerned on the 27th, the indication expansion application which was turned...
Will it be ok to allow patients to purchase household medicines with no prescriptions?
Household medicines have become a trend. However, its following side effects have raised concerns as well.
According to the Statistics for Distribution Information of Complete Drugs published by the Health Insurance ...
‘Clear’ downtrends of major hypertension treatments
Downtrends of major hypertension treatments have become obvious.
It was observed only did 3 of 15 antihypertensive drugs have higher outpatient prescriptions in the 3rd quarter than the record of the last year.
Acco...
Mixed feelings of ETC drugs in actual output
The last year’s top 10 ETC drugs in annual sales had mixed feelings this year.
According to the ‘First Half’s Actual Outputs of Domestic ETC Drugs’ reported to the Ministry of Food and Drug Safety(MFDS), 6 of the top...
‘Lipitor’ in a great shape, getting away from the second largest one
In the hyperlipidemia field, Lipitor(developed by Pfizer) has remained strong. Its gap with Crestor, the second largest drug, has been expended since the beginning of the year.
Lipitor, which almost got caught, was a...
Viread’s explosive growth to KRW 100 billion prescriptions
‘Viread,’ the new star of the hepatitis B treatment market, will list its name for the gigantic products which record KRW 100 billion outpatient prescriptions.
Until the last year, products exceeding annual KRW 100 b...
TPP raises concern in TTP pharmaceutical field
It was analyzed the TPP(Trans-Pacific Partnership) agreement may create a negative impact as causing significant influence on approval and benefit of the pharmaceutical policy.
Kyung-bok Sohn(the primary author, Seou...
